Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Britain's AstraZeneca launches $1 billion China investment fund with CICC

share with twitter share with LinkedIn share with facebook
share via e-mail
11/06/2019 | 05:01am EST
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters.

AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said. The companies did not disclose financial details of the deal.

"It's a substantial investment on our side, but also our financial partners," Soriot said of the agreement, to be signed with the Chinese investment bank CICC on the sidelines of the China International Import Expo on Wednesday.

"We can help choose some of those investments but we can also help along the way the startup companies, develop products and find their way around the world" he said, describing it as AstraZeneca's largest-scale healthcare industrial fund.

The company also planned to expand an existing research and development centre in Shanghai from 450 employees to 1,000, and establish a new artifical intellgience innovation centre in the city.

Western drugmakers have profited from partnerships in China, where AstraZeneca's sales have doubled since 2012, as well as a softening in the regulatory environment for pharmaceutical firms.

But the government has also been trying to slash drug prices, changing the playing field as many firms had relied in the past on selling older drugs at premium prices. In September, China also expanded a pilot bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers.

Soirot said these were both factors in AstraZeneca's decision to make those investments in China, as the price pressures were encouraging companies to create new drugs that the government was approving and reimbursing at a faster pace.

AstraZeneca, he said, wanted to start making drugs it could export globally from China. Areas of opportunity included oncology and respiratory diseases.

"Historically, until today, our Chinese team has been developing global products for the Chinese market. We want now the Chinese team to take the global leadership on some projects," he said.

(Reporting by Brenda Goh; Editing by Stephen Coates)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.04% 7297 Delayed Quote.-4.04%
CHINA INTERNATIONAL CAPITAL CORPORATION LIMITED 1.10% 14.66 End-of-day quote.-2.91%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
DJ
02/14EUROPE : European shares settle below record highs
RE
02/14FTSE 100 ends week lower after week AstraZeneca, RBS results
RE
02/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/14GLOBAL MARKETS LIVE: Facebook ready to pay more taxes, Amazon gets JEDI suspe..
02/14AstraZeneca's CEO reaffirms 2021 targets
RE
02/14AstraZeneca braces for coronavirus hit, but no impact so far
RE
02/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/14ASTRAZENECA : 4Q Earnings Snapshot
AQ
02/14NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 27 045 M
EBIT 2020 7 358 M
Net income 2020 2 965 M
Debt 2020 12 226 M
Yield 2020 2,98%
P/E ratio 2020 38,2x
P/E ratio 2021 25,3x
EV / Sales2020 5,07x
EV / Sales2021 4,58x
Capitalization 125 B
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 106,29  $
Last Close Price 95,24  $
Spread / Highest target 45,4%
Spread / Average Target 11,6%
Spread / Lowest Target -21,7%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-4.04%124 785
JOHNSON & JOHNSON2.92%395 123
ROCHE HOLDING AG9.79%294 912
NOVARTIS4.27%220 633
MERCK AND COMPANY-9.13%210 426
PFIZER-6.81%202 051